| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Flavonoid glycoside. Responsible for the bitterness of grapefruit. Naringin is a flavonoid glycoside predominantly found in citrus fruits such as grapefruit and oranges. It is known for its antioxidant, anti-inflammatory, and potential anticancer properties. It is hydrolyzed in vivo to naringenin, which exhibits antioxidant and anti-inflammatory activities and modulates signaling pathways (e.g., Nrf2 and NF-κB). In preclinical cancer models, naringin/naringenin is associated with cell-cycle arrest, apoptosis, and reduced invasion/metastasis, often linked to upstream modulation of survival pathways (PI3K/AKT) and stress MAPKs. Oral systemic exposure is limited due to metabolism and conjugation. -Antioxidant Activity -Induction of Apoptosis -Cell Cycle Arrest (often G1 or G2/M) -Anti-inflammatory Effects -**a natural bioenhancer(effects vary) and reported to enhance the bioavailability of drugs by inhibiting cytochrome P450 (CYP3A4 especially grape fruit juice) and P-glycoprotein (P-gp). Naringin/naringenin can inhibit CYP3A4 and P-glycoprotein, contributing to grapefruit–drug interactions and potentially increasing exposure of certain medications. -Usually paired with other bioflavonoids such as quercetin, hesperidin and rutin. -Mainly obtained from grapefruit -Including enhanced solubility, improved bioavailability and targeted delivery. -Antioxidant -Inhibition of CYP19(weak/modest). Naringin suppresses the PI3K/AKT signalling pathway -Wnt/β-catenin, PI3K/Akt, NF-ĸB, and TGF-β pathways -Up-regulation of adenosine monophosphate-activated protein kinase (AMPK), and inhibition of gluconeogenesis -Antioxidant effects, by modulating reactive oxygen species (ROS) levels and increasing superoxide dismutase (SOD) -Naringenin can reduce carcinogenesis through pleiotropic processes such as antioxidative, apoptotic-inducing ROS generation, and cell cycle arrest -Revealed new mechanisms underlying the hypolipidemic effects of naringin and naringenin, including regulation of lipid digestion, reverse cholesterol transport, and low-density lipoprotein receptor expression -Low bioavailability (approximately 8.8%) when administered orally. Bioavailability: citrus flavonoid glycosides are hydrolyzed in the gut; systemic plasma levels are often much lower than in vitro MICs.
Time-Scale Flag (TSF): P / R / G
|
| Source: HalifaxProj(inhibit) |
| Type: |
| A family of enzymes that play a crucial role in the signaling pathways of various cytokines and growth factors. They are involved in the regulation of immune responses, hematopoiesis, and cell proliferation. Dysregulation of JAK signaling has been implicated in several types of cancer, particularly hematological malignancies such as leukemia and lymphoma. Targeting JAKs with specific inhibitors has emerged as a therapeutic strategy in oncology. JAK inhibitors, such as ruxolitinib and tofacitinib, are used to treat certain blood cancers and autoimmune diseases. These drugs work by blocking the activity of JAKs, thereby inhibiting the signaling pathways that promote cancer cell proliferation and survival. |
| 1803- | NarG, | Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:128 Target#:162 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid